Richard Lowenthal, MS, MSEL
M r. Richard Lowenthal possesses more than 25 years of experience in strategic drug development, project leadership, regulatory affairs, and quality assurance. Mr. Lowenthal has extensive experience with strategic global development as well as product registration of new drugs and biologics in the United States, Europe, and Japan. As founder of Pacific-Link Regulatory Consulting, Mr. Lowenthal is dedicated to the support of pharmaceutical, biotechnology, and investment companies, providing leadership and mentoring on regulatory affairs, clinical development, quality assurance, licensing, and investment opportunities. Mr. Lowenthal has led the regulatory efforts at Neurelis since its inception in 2007.
Previously, Mr. Lowenthal has served as Vice President, Regulatory Affairs and Quality Assurance for Cadence Pharmaceuticals; Head of Worldwide Regulatory Affairs, Quality Assurance and Drug Safety for Maxim Pharmaceuticals, Inc.; Vice President of Regulatory Affairs and Quality Assurance for AnGes, MG, Inc.; Global Project Leader and Global Director Regulatory Affairs for Janssen Research Foundation; Director of Regulatory Affairs and Quality Assurance of Somerset Pharmaceuticals Inc.; and as a New Drug Review Chemist for the US Food and Drug Administration in the Division of Neuropharmacologic Drug Products and the Division of Oncology and Pulmonary Drug Products.
Mr. Lowenthal holds an MS in Organic Chemistry from Florida State University and Masters in Business Science for Executive Leadership (MSEL) from the University of San Diego. Mr. Lowenthal has served as past Chair of the San Diego region for AAPS, as Member of the USP Biotechnology Expert Committee, Chair of the Virology Working group, Member of the National Organization of Rare Disease (NORD) Corporate Council, and with various PhARMA and ICH Working Groups.